|
業務類別
|
Biotechnology |
|
業務概覽
|
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. |
| 公司地址
| 1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139 |
| 電話號碼
| +1 786 977-3380 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pasithea.com |
| 員工數量
| 5 |
| Mr. Daniel Schneiderman |
Chief Financial Officer and Principal Accounting Officer |
美元 330.00K |
30/03/2026 |
| Dr. Tiago Reis Marques |
Chief Executive Officer and Director |
美元 450.00K |
30/03/2026 |
|
|
| Professor Lawrence J. Steinman, M.D. |
Executive Chairman of the Board |
30/03/2026 |
| Mr. Alfred J Novak |
Independent Director |
30/03/2026 |
| Dr. Tiago Reis Marques |
Chief Executive Officer and Director |
30/03/2026 |
| Mr. Simon Dumesnil |
Independent Director |
30/03/2026 |
| Dr. Emer Leahy, PhD |
Independent Director |
30/03/2026 |
|
|
|
|
